Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials – investor.lilly.com

For years, the narrative around weight loss has been a cycle of triumph followed by the inevitable “bounce back.” You lose the weight, you feel incredible, and then—almost as if your body has a biological memory of its heaviest state—the pounds return. This phenomenon, often called weight regain, has been the Achilles’ heel of obesity treatment, whether through traditional dieting or early pharmacological interventions.

However, we are entering a new era of metabolic medicine. The conversation is shifting from how we lose weight to how we keep it off. Recent breakthroughs in incretin therapies are suggesting that the “all-or-nothing” approach to weight-loss drugs—where patients either stay on a maximum dose forever or quit and risk regain—is becoming obsolete.

The Battle Against the “Rubber Band Effect”

Weight regain isn’t a failure of willpower; it’s a failure of biology. When we lose significant weight, our bodies often trigger a survival response, slowing the metabolism and increasing hunger hormones to push us back to our previous weight. This is what clinicians call the “rubber band effect.”

According to industry experts, including Dr. Louis J. Aronne, weight regain is one of the most significant challenges in obesity care, often caused by treatment interruptions that allow biology to work against the patient [4]. The goal now is to find a “maintenance cruise control” that keeps the weight off without requiring maximum medication levels indefinitely.

From Needles to Pills: The Rise of Maintenance Therapy

The most exciting trend in current obesity research is the “step-down” strategy. Instead of stopping medication entirely, patients are transitioning from high-dose injectables to more manageable maintenance options. This is where Eli Lilly and Company is making significant strides with medications like Foundayo and Orforglipron.

The Foundayo and Orforglipron Breakthrough

Recent late-phase trials, including ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, have provided a glimpse into a future where a daily pill replaces the weekly jab for long-term weight stability. The data is compelling:

• Seamless Transitions: In the ATTAIN-MAINTAIN trial, participants who switched from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained nearly all of their weight loss, regaining an average of only 0.9 kg over one year [4].
• Pill vs. Injection: For those switching from Zepbound MTD to Foundayo, the average regain was approximately 5.0 kg over a year—a far cry from the massive regain often seen when stopping therapy entirely.

This shift toward oral medications not only improves patient compliance by removing “needle phobia” but also allows for more precise dosing adjustments as a patient moves from the active weight-loss phase to the maintenance phase.

Tailoring the Dose: Is “Less” Actually “More”?

Another emerging trend is the use of lower-dose versions of existing injectables to maintain results. The SURMOUNT-MAINTAIN study revealed that participants who reduced their Zepbound dose to 5 mg maintained most of their weight loss (regaining an average of 5.6 kg) compared to those on the maximum dose who maintained all of it [4].

This suggests a future of personalized metabolic titration. Rather than a one-size-fits-all dose, doctors may soon prescribe a “loading dose” for rapid loss and a “maintenance dose” tailored to the individual’s specific biological set-point. This approach minimizes side effects and reduces the long-term cost of treatment.

The Future of Obesity Management: A Lifelong Journey

The overarching trend is the medicalization of obesity as a chronic condition rather than a temporary problem to be “fixed.” Just as a person with hypertension takes medication to maintain healthy blood pressure, the future of weight management will likely involve long-term, low-dose maintenance.

We can expect to see more “combination therapies” emerging—perhaps a potent injectable for the first six months, followed by a daily oral tablet like Orforglipron to lock in the results. This hybrid approach addresses both the need for rapid initial intervention and the requirement for sustainable, lifestyle-friendly maintenance.

For those looking to optimize their health, it’s worth exploring how these medications integrate with broader lifestyle changes. You can read more about optimizing your metabolic health and nutrition for long-term weight stability on our site.

Frequently Asked Questions

Q: Can I stop taking weight-loss injections entirely without regaining weight?
A: While some can, many experience regain due to biological triggers. New research suggests that transitioning to a maintenance dose or an oral pill (like Foundayo) is more effective than stopping abruptly.

Q: What is the difference between Zepbound and Foundayo?
A: Zepbound is typically an injectable incretin therapy used for weight loss, while Foundayo is an oral alternative designed to help maintain that weight loss after an initial period of treatment.

Q: How much weight is typically regained when switching to maintenance therapy?
A: Data varies by trial, but some patients switching from high-dose injectables to oral maintenance regained as little as 0.9 kg over a year, depending on the specific medication used.